Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Michigan and ephedrine

This article was originally published in The Tan Sheet

Executive Summary

Foods or dietary supplements containing less than 25 mg ephedrine alkaloids or the limits set in upcoming FDA regs excluded from the state's Schedule V controlled substances list under Senate bill 182, signed by Gov. John Engler Oct. 22. The bill also sets a 100 mg ephedrine alkaloids daily limit, prohibits administration of such products to people under 18 (unless by a physician or parent) and forbids euphoria or sexual performance claims. OTC products also would be exempted if made and distributed in a manner consistent with their applicable monograph. OTCs must be in a solid dosage form in blister packs and contain at least 400 mg guaifenesin and, at most, 25 mg ephedrine per dose; anorectal preparations could contain up to 5% ephedrine. The bill, which takes effect 90 days after its passage, is nearly identical to Ohio legislation passed in December 1996

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts